Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Associate Editor's Commentary: Measuring Responsibility.

Peter J Pitts1

  • 11 Center for Medicine in the Public Interest, New York, NY, USA.

Therapeutic Innovation & Regulatory Science
|September 21, 2018
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

COVID-19 vaccine policy: a response and way forward.

Vaccine·2026
Same author

Transforming Objective Participatory Patient Advocacy.

Therapeutic innovation & regulatory science·2025
Same author

Equity and capacity to benefit from early access to medicines schemes.

International journal for equity in health·2025
Same author

Healthcare Futures: Opportunities, Challenges and Risks in a Blockchain-Driven Environment.

Blockchain in healthcare today·2025
Same author

Addressing vaccine misinformation: The critical need for complete product information disclosure.

Vaccine·2024
Same author

Addressing vaccine hesitancy: Learning from the successes and failures of the COVID-19 pandemic.

Vaccine·2024
Same journal

Understanding the Added Value of Action Limits for QTL Monitoring.

Therapeutic innovation & regulatory science·2026
Same journal

Implementing Project Optimus in Oncology Dosage Optimization: Where are We Now?

Therapeutic innovation & regulatory science·2026
Same journal

Validation of the Ontario Protocol Assessment Level (OPAL) Tool for Assessing Clinical Trial Complexity and Supporting Workforce Planning in the Italian Clinical Research Context.

Therapeutic innovation & regulatory science·2026
Same journal

The Effect of Covariate Adjustment for Cox Regression in Cardiovascular Outcome Trials.

Therapeutic innovation & regulatory science·2026
Same journal

Current Status and Construction Requirements of Drug Clinical Trial Institutions in Sichuan Province in China.

Therapeutic innovation & regulatory science·2026
Same journal

The CARE Program: An Initiative of Patient-Focused Drug Development for Rare Diseases by NMPA.

Therapeutic innovation & regulatory science·2026
See all related articles

The Access to Medicine Index (ATMi) evaluates pharmaceutical companies' corporate social responsibility. It aims to improve global medicine access by fostering competition among companies for better practices.

Area of Science:

  • Pharmaceutical industry analysis
  • Global health equity
  • Corporate social responsibility

Background:

  • The Access to Medicine Index (ATMi) is a comparative tool.
  • It assesses innovator and generics pharmaceutical companies.
  • The index uses various indicators to measure corporate social responsibility.

Purpose of the Study:

  • To measure and compare the corporate social responsibility of pharmaceutical companies.
  • To encourage improvements in pharmaceutical industry commitments and practices.
  • To facilitate access to medicines for underserved populations globally.

Main Methods:

  • The ATMi employs a range of indicators to evaluate companies.
  • It compares both innovator and generics pharmaceutical firms.
Keywords:
access to medicinescorruptiondrug pricinggeneric drugsinnovationintellectual propertypatentsrational use of drugs

Related Experiment Videos

  • Data is collected and analyzed by the Access to Medicine Foundation.

    • Main Results:

    • The index provides a comparative ranking of pharmaceutical companies.
    • It highlights differences in corporate social responsibility efforts.
    • The effectiveness of competition as a driver for improved practices is implied.

    Conclusions:

    • The ATMi serves as a mechanism to encourage pharmaceutical companies towards greater social responsibility.
    • The ultimate goal is to enhance access to essential medicines in developing countries.
    • The index's utility lies in its ability to foster competition for improved global health outcomes.